Home
Clinical Trials
Registry of Patients Treated ...

Registry of Patients Treated With Systemic Mold-Active Triazoles

Last Updated: 2024-10-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2015 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-16

Study Completion Date

2020-04-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing

NCT01416025

Fungal Infection

COMPLETED PHASE4

A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

NCT01782131

Fungal Infections Invasive Pulmonary Aspergillosis

COMPLETED PHASE3

PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.

NCT03121235

Aspergillosis, Invasive Pulmonary

COMPLETED

Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study

NCT06069505

Invasive Aspergillosis

RECRUITING

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

NCT00001810

Aspergillosis Candidiasis Fungemia +1 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Invasive Fungal Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Isavuconazonium sulfate Group

Oral and Intravenous

Isavuconazonium sulfate

Intervention Type DRUG

Oral and Intravenous

Voriconazole Group

Oral and Intravenous

Voriconazole

Intervention Type DRUG

Oral and Intravenous

Posaconazole Group

Oral and Intravenous

Posaconazole

Intervention Type DRUG

Oral and intravenous

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Isavuconazonium sulfate

Oral and Intravenous

Intervention Type DRUG

Voriconazole

Oral and Intravenous

Intervention Type DRUG

Posaconazole

Oral and intravenous

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cresemba Vfend Noxafil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients taking one of the following target drugs at the time of enrollment: isavuconazonium sulfate (ISAV), voriconazole (VORI), posaconazole (POSA).

Exclusion Criteria

* Currently enrolled in any clinical trial with an investigational antifungal agent. Individuals who subsequently enroll in an investigational antifungal study will be discontinued and data collected up to the time of investigational product will be evaluable.
* Patients who died before entering the study.
* Patients who previously participated in this registry.

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Senior Medical Director

Role: STUDY_DIRECTOR

Astellas Pharma Global Development, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama - Birmingham

Birmingham, Alabama, United States

Site Status

St. Joseph's Hospital

Phoenix, Arizona, United States

Site Status

Mayo Clinic

Phoenix, Arizona, United States

Site Status

University of Arizona

Tucson, Arizona, United States

Site Status

University of California

Davis, California, United States

Site Status

David Geffen School of Medicine

Los Angeles, California, United States

Site Status

Stanford Health Care

Palo Alto, California, United States

Site Status

Olive View UCLA Medical Center

Sylmar, California, United States

Site Status

LA BioMed

Torrance, California, United States

Site Status

University of Colorado

Aurora, Colorado, United States

Site Status

Yale School of Medicine

New Haven, Connecticut, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status